Scope and Patent Landscape of US Drug Patent 9,295,642 (Extended-Release Racemic Methylphenidate Chewable Tablet)
US Patent 9,295,642 claims an extended-release (ER) racemic methylphenidate chewable tablet with a specific dual-immediate plus sustained-release architecture built around methylphenidate-ion exchange resin complexes and a pH-independent, water-insoluble, water-permeable barrier coating applied over a polymeric matrix containing the sustained-release complex. The independent claim (Claim 1) tightly couples composition structure, relative weight fractions, barrier-coating material specifications, and pharmacokinetic (PK) targets at a defined single-dose exposure window (adults, 40 mg equivalent racemic methylphenidate HCl, fasted and fed).
This combination creates a scope that is narrow on formulation specifics but broad on functional PK outcomes, with multiple fallback layers (dependent claims) that narrow further through coating chemistry, resin-complex proportions, tensile strength, hardness, and PK metrics.
What is the core invention in Claim 1?
Claim 1 defines an ER racemic methylphenidate chewable tablet that is a uniform solid dispersion comprising three pharmacokinetic “modules”:
(a) Sustained-release module (core ER engine)
- Sustained release racemic methylphenidate component comprising:
- a water-insoluble, water-permeable, pH-independent barrier coated
- racemic methylphenidate-ion exchange resin complex-matrix
- where the barrier coating is “over” the complex-matrix
- the barrier coating provides the sustained release profile
(b) First immediate-release module (slower onset of release)
- First immediate release component:
- immediate release uncoated racemic methylphenidate-ion exchange resin complex
(c) Second immediate-release module (faster onset of release)
- Second immediate release racemic methylphenidate component:
- uncomplexed racemic methylphenidate (or pharmaceutically acceptable salt; dependent claims specify HCl)
Onset ordering requirement
- The first immediate release component (b) has a slower onset of release than (c).
Relative composition fractions (key scope limiter)
- 50% w/w to 90% w/w of the racemic methylphenidate active component is provided by the sustained release component, based on total racemic methylphenidate in the tablet.
Dose equivalence and ER/PK performance
Single-claim “center of gravity”
Claim 1 scope is anchored by the coated resin complex (a + barrier coating over complex-matrix), combined with a two-part immediate release split (b uncoated resin complex, c uncomplexed salt), plus explicit weight fraction boundaries for the sustained portion and explicit PK target ranges.
How do dependent claims narrow or re-shape the scope?
Below are the main dependent claim “carve-outs” and their practical litigation value.
PK tightening (Claims 2, 3, 22–26)
- Claim 2: Cmax about 12 to 13 ng/mL
- Claim 3: AUC0-∞ about 113 to 138 ng·hr/mL
- Claim 22: PK has a single mean plasma concentration peak
- Claim 23: Peak occurs 4 to 5.25 hours (fasted and fed)
- Claim 24: includes 90% confidence intervals for test/reference ratios of AUC0-3 or AUC0-4 of FIG. 1
- Claim 25: AUC0-3 about 18 ng·hr/mL (bioequivalent target)
- Claim 26: 0 to 8 hour concentration profile equivalent to FIG. 1
Impact: These dependent claims increase the likelihood that a narrow formulation that hits the targeted PK curve lands inside the patent’s measured boundary conditions. They also create potential infringement arguments based on empirical PK matching, especially where regulators reference the same comparative figures.
What formulation elements are most important to infringement analysis?
1) Sustained-release barrier coating specification (Claims 13–15, 18)
The patent does not claim “any barrier coating.” It specifies a pH-independent, water-insoluble, water-permeable barrier with defined tensile strength and candidate chemistries.
-
Claim 13: barrier coating tensile strength 150% to 400% and selected from:
- (a) cured, water-permeable, non-ionic, pH-independent coating with polyvinylacetate + stabilizer + plasticizer as aqueous dispersion
- (b) ionic, pH-independent, acrylic-based coating with polymer/copolymer containing ethyl acrylate and methyl methacrylate as aqueous dispersion
- (c) solvent-based ethylcellulose coating, optionally with plasticizer
-
Claim 14: barrier coating (a) is specifically:
- 70% to 90% w/w polyvinylacetate
- 2% to 10% w/w plasticizer
-
Claim 15: barrier coating layer is 25% to 35% by weight of the coated complex-matrix
-
Claim 18: barrier coating uses an acrylic-based blend of two polymer ratios:
- ratio set: 1:2:0.1 and 1:2:0.2 for components of
poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride)
Impact: These elements are likely the most direct formulation design constraints. Competitors attempting to use different polymer systems, different tensile properties, or non-matching pH dependence face a scope mismatch.
2) Ratio of immediate-release modules (Claims 5–7, 11)
The claims insist on both the presence and relative proportions of immediate-release components.
- Claim 5: uncoated resin complex (b) + uncomplexed methylphenidate (c) together comprise 20% to 40% w/w of total methylphenidate in the tablet
- Claim 6: mass ratio of (b):(c) is about 3:1 based on total weight of immediate release components
- Claim 7: uncoated resin complex (b) is 5% to 35% w/w of total methylphenidate
- Claim 11: example split:
- uncoated resin complex (b) about 15% w/w
- uncomplexed methylphenidate (c) about 15% w/w
- (computed from total racemic methylphenidate)
Impact: The patent’s immediate-release “identity” is not just “IR.” It specifically requires two immediate-release sources that have different onset kinetics, with an approximate 3:1 split between uncoated resin complex and uncomplexed methylphenidate.
3) Complex vs uncomplexed salt identities (Claims 8–10)
- Claim 8: uncomplexed methylphenidate is a pharmaceutically acceptable salt
- Claim 9: salt is racemic methylphenidate HCl
- Claim 10: uncomplexed methylphenidate (c) is 5% to 35% w/w
Impact: Most meaningful for freedom-to-operate (FTO) where applicants swap salts or use non-HCl forms. The independent claim allows “acceptable salt,” but dependent claims tighten to HCl, making HCl-centric commercial embodiments more exposed.
4) Sustained portion mass range (Claim 4)
- Claim 4: sustained-release component provides 60% to 80% w/w of methylphenidate in tablet
Impact: Together with Claim 1’s 50% to 90% range, Claim 4 narrows the typical commercial window.
5) Matrix and uniform dispersion requirement (Claims 1, 16–17)
- Claim 1: chewable tablet is a uniform solid dispersion
- Claim 16: polymeric matrix comprises polyvinylpyrolidone
- Claim 17: matrix further comprises a water-insoluble polymer
Impact: This matters most where competitors build ER using different matrix platforms (osmotic systems, multiparticulate beads without a solid dispersion definition, or different hydrophilic/hydrophobic carriers).
6) Tablet physical property (Claim 12)
Impact: Not typically the primary determinant in infringement, but it can become a gating parameter for stability/handling and for claim mapping in manufacturing.
7) Divisibility with retained ER profile (Claim 1)
- Tablet portions retain therapeutically effective extended release profile when divided.
Impact: This targets scored/divisible chewable tablets. It can constrain design-around strategies that rely on intact-dosage-only profiles.
8) PK shape and dose profile equivalence to a figure (Claims 22–26)
- single peak, time-to-peak, confidence interval relationships, and curve equivalence to FIG. 1
Impact: The patent’s infringement story can be anchored to the exact PK profile used in prosecution or bioequivalence testing, which is often regulator-aligned.
What does Claim 1 cover in operational terms? (Scope map)
| Claim element |
What it requires |
Design implication |
| Sustained release |
coated, water-insoluble, water-permeable, pH-independent barrier over resin complex-matrix |
Barrier polymer family and performance properties are constrained |
| Immediate release (b) |
uncoated methylphenidate-ion exchange resin complex |
Must use uncoated resin complex for slower-onset IR |
| Immediate release (c) |
uncomplexed racemic methylphenidate acceptable salt (HCl in dependent claims) |
Salt form and uncomplexed identity constrained |
| Onset ordering |
(b) slower than (c) |
Empirical release kinetics must match the ordering |
| Sustained fraction |
50% to 90% of methylphenidate from sustained component (and 60%-80% in Claim 4) |
ER loading range is constrained |
| Tablet |
uniform solid dispersion, chewable, divisible/ scored (Claim 29) |
Manufacturing format limited |
| PK targets |
AUC0-∞ and/or Cmax in stated ranges after 40 mg racemic methylphenidate HCl eq |
Must meet numeric exposure boundaries |
| PK shape |
single mean peak; peak time 4-5.25h; AUC confidence interval targets |
Strong alignment to one comparative PK dataset |
How does Claim 29 and divisibility shape the landscape?
- Claim 29: tablet is scored
- Claim 1 also requires dividability with retained ER profile.
Landscape effect: If an alternative ER chewable format is not scored or does not preserve ER when split, it may fall outside claim 1 even if PK ranges are met.
What is the competitive risk profile? (Infringement hotspots)
Highest-risk embodiments
- ER racemic methylphenidate chewables using:
- an ER engine built from coated methylphenidate-ion exchange resin complexes in a polymeric matrix
- uncoated resin complex for slower IR
- uncomplexed racemic methylphenidate HCl for faster IR
- Formulations meeting:
- sustained fraction (50% to 90%, often 60% to 80%)
- immediate split around 3:1 (b:c)
- barrier coating definitions (water-insoluble, water-permeable, pH-independent) and candidate polymers (PVA-based or acrylic blend or ethylcellulose)
- measured PK ranges after 40 mg equivalent dose
Lower-risk (but still fact-dependent) design-arounds
- Different barrier chemistry outside the listed options or outside the tensile strength and layer weight constraints
- IR strategy using only one immediate-release source (no split between uncoated resin complex and uncomplexed salt)
- Replacing uncomplexed HCl with a different salt form may avoid dependent claim coverage but not independent claim (acceptable salt still counts), so it is not a total escape
Patent landscape: what can be inferred from the claim architecture
Without the rest of the patent family data (priority, related continuations, and cited art), the landscape must be inferred from claim construction signals.
1) Claim style indicates a formulation-and-parameter “platform”
The independent claim mixes:
- structural requirements (coated resin complex-matrix; uniform solid dispersion)
- material properties (barrier is water-insoluble, water-permeable, pH-independent)
- quantitative ratios (50%-90% sustained loading; IR 20%-40%; b:c ~3:1)
- functional PK equivalence (AUC0-∞, Cmax ranges; AUC0-3 equivalence; curve equivalence to FIG. 1)
- physical constraints (hardness, divisibility)
This pattern implies the patent likely anchors a specific commercial product profile: chewable ER methylphenidate racemate with defined exposure windows under fasted and fed states.
2) Dependent claims track multiple “likely commercial variations”
Dependent claims create fallback coverage for:
- PK narrowing (Claims 2, 3, 22–26)
- barrier polymer choices (Claims 13–15, 18)
- matrix composition (Claims 16–17)
- tablet engineering (hardness; scored)
This is typical where competitors may shift barrier polymer and still attempt to keep the same ER PK. The patent anticipates those shifts by claiming a menu of barrier systems while still demanding coating pH-independent and water permeability/insolubility behavior.
3) The resin complex is the pivotal technological anchor
Because both sustained and slower immediate release are based on methylphenidate-ion exchange resin complexes, the patent likely creates a blocking position against:
- switching to purely uncomplexed ER systems
- switching to multiparticulates lacking this coated-uncoated resin split
- removing the resin complex layer from the ER engine
Practical freedom-to-operate checklist tied to these claims
A product maps into the patent faster if it matches the following checkpoints:
- Chewable ER racemic methylphenidate with uniform solid dispersion definition.
- ER includes pH-independent barrier coated methylphenidate-ion exchange resin complex-matrix.
- Immediate release includes uncoated resin complex (slower onset).
- Immediate release also includes uncomplexed racemic methylphenidate (faster onset), preferably HCl.
- Sustained fraction and IR fraction stay within:
- sustained 50%-90% (and/or 60%-80%)
- immediate total 20%-40%
- IR ratio (b):(c) about 3:1.
- Barrier coating matches the polymer menu and specified constraints (tensile strength; PVA/plasticizer %; layer weight; or acrylic blend ratios).
- PK after 40 mg racemic methylphenidate HCl equivalent lands within AUC0-∞ 110-140 and/or Cmax 10-15, plus the single peak and 4-5.25 hour time window.
Key Takeaways
- US 9,295,642 claims an ER racemic methylphenidate chewable built from a coated resin complex sustained-release engine plus a two-source immediate release system: uncoated resin complex (slower onset) and uncomplexed methylphenidate salt (faster onset).
- The claim scope is driven by specific coating constraints (pH-independent, water-insoluble/water-permeable barrier; tensile strength; polymer-specific options; layer weight) and specific quantitative splits (sustained 50%-90%, immediate total 20%-40%, and b:c about 3:1).
- The patent also ties infringement to numeric PK outcomes after a defined single dose (40 mg racemic methylphenidate HCl equivalent) and to PK curve shape (single peak and peak timing).
- The landscape risk concentrates on products that preserve both the resin-complex coated/uncoated split and the barrier coating identity while targeting the same ER PK profile.
FAQs
1) Does Claim 1 require that both immediate-release components exist in the tablet?
Yes. Claim 1 requires both: (b) uncoated racemic methylphenidate-ion exchange resin complex and (c) uncomplexed racemic methylphenidate (salt acceptable).
2) Can a product avoid the patent by changing the uncomplexed salt from HCl?
Dependent claims specify HCl, but Claim 1 allows “acceptable salt.” A salt change alone does not eliminate independent-claim coverage if other elements match.
3) Is the barrier coating required to be specific polymer types or just functional behavior?
It must match functional behavior (water-insoluble, water-permeable, pH-independent), and dependent claims further require tensile strength and specific listed coating material systems.
4) Are PK metrics mandatory for infringement?
Claim 1 includes PK ranges as part of the claimed tablet’s pharmacokinetic profile, so the tablet is characterized by those PK outcomes.
5) Does divisibility matter?
Yes. Claim 1 requires that the tablet can be divided and the divided portions retain a therapeutically effective extended release profile, and Claim 29 adds that the tablet is scored.
References
[1] United States Patent No. 9,295,642. Extended release racemic methylphenidate chewable tablet.
